Pacira BioSciences (PCRX) Cash & Current Investments (2010 - 2026)

Pacira BioSciences' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $202.2 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 59.04% year-over-year to $202.2 million in Q1 2026; TTM through Mar 2026 was $202.2 million, a 59.04% decrease from a year earlier, with the FY2025 full-year figure at $238.4 million, down 50.8% from the prior year.
• Cash & Current Investments slipped to $202.2 million in Q1 2026 per PCRX's latest filing, from $238.4 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $493.6 million in Q1 2025 and bottomed at $174.0 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $316.4 million (2022), against an average of $328.8 million.
• Across the five-year window, Cash & Current Investments slumped 61.52% in 2023 and soared 92.96% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $288.7 million in 2022, then retreated by 3.49% to $278.6 million in 2023, then surged by 73.96% to $484.6 million in 2024, then plunged by 50.8% to $238.4 million in 2025, then slipped by 15.2% to $202.2 million in 2026.
• Per Business Quant, the three latest PCRX Cash & Current Investments figures stand at $202.2 million (Q1 2026), $238.4 million (Q4 2025), and $246.3 million (Q3 2025).